Antidepressant efficacy and tolerability of the selective norepinephrine reuptake inhibitor reboxetine: A review

Journal of Clinical Psychiatry

Volumn 59, Issue SUPPL. 14, 1998, Pages 4-7

  Burrows, Graham D ^a   Maguire, Kay P ^a   Norman, Trevor R ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

NORADRENALIN UPTAKE INHIBITOR; REBOXETINE; TRICYCLIC ANTIDEPRESSANT AGENT;

CLINICAL TRIAL; DEPRESSION; DRUG EFFICACY; DRUG TOLERABILITY; DYSTHYMIA; HEADACHE; HUMAN; INSOMNIA; PRIORITY JOURNAL; RATING SCALE; RELAPSE; REVIEW; SWEATING; TREATMENT OUTCOME; VISUAL IMPAIRMENT; XEROSTOMIA;

ADOLESCENT; ADRENERGIC UPTAKE INHIBITORS; ADULT; AGE FACTORS; AGED; CLINICAL TRIALS; DEPRESSIVE DISORDER; DRUG ADMINISTRATION SCHEDULE; DYSTHYMIC DISORDER; HUMANS; MIDDLE AGED; MORPHOLINES; MULTICENTER STUDIES; NOREPINEPHRINE; TREATMENT OUTCOME;

EID: 0031716123     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (12)

1. Leonard BE. Noradrenaline in basic models of depression. Eur Neuropsychopharmacol 1997;7(suppl 1):S11-S16
2. Melloni P, Carneil G, Della Torre A, et al. Potential antidepressant agents, α-aryloxy-benzyl derivatives of ethanolamine and morpholine. Eur J Med Chem 1984;19:235-242
3. Riva M, Brunello N, Rovescalli AC, et al. Effect of reboxetine, a new antidepressant drug, on the central noradrenergic system: behavioural and biochemical studies. J Drug Dev Clin Pract 1989;1:243-253
4. Berzewski H, Van Moffaert M, Gagiano CA. Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive episodes. Eur Neuropsychopharmacol 1997;7(suppl 1):S37-S47
5. Dubini A, Bosc M, Polin V. Do noradrenaline and serotonin differentially affect social motivation and behaviour? Eur Neuropsychopharmacol 1997;7(suppl 1):S49-S55
6. Ban TA, Gaszner P, Aguglia E, et al. Clinical efficacy of reboxetine: a comparative study with desipramine - with methodological considerations. Hum Psychopharmacol 1998;13:S29-S39
7. Massana J. Reboxetine versus fluoxetine: an overview of efficacy and tolerability. J Clin Psychiatry 1998;59(suppl 14):8-10
8. American Psychiatric Association. Mood disorders. In: Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised. Washington, DC: American Psychiatric Association; 1987:213-233
9. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
10. Montgomery SA, Asberg MA. New depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-389
11. Guy W. Clinical Global Impressions. In: ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:218-222
12. Dostert P, Benedetti MS, Pogessi I. Review of the pharmacokinetics and metabolism of reboxetine, a selective noradrenaline reuptake inhibitor. Eur Neuropsychopharmacol 1997;7(suppl 1):S23-S35